Log in Free sign up

Dare Bioscience (DARE) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Biotech, Earnings, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Dare Bioscience: Q1 Earnings Insights

Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Dare Bioscience Q1 EPS $(0.10) Beats $(0.14) Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 41.18 percent increase over losses of $(0.17) per share from

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

Earnings Preview: Dare Bioscience

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.14.

Dare Bioscience Reports Notice Of Award Of Grant From Eunice Kennedy Shriver National Institute Of Child Health For ~$249K 'to support end-user research, including surveys of approximately 1,000 women in the U.S. ages 18-44 years...'

Biotech, News, FDA, General

Supports research to define end-user preferences among U.S. women to inform the design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel designed to

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Daré Bioscience Initiates Phase 1/2 Clinical Study Of DARE-HRT1

Biotech, News, FDA, General

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1. DARE-HRT1 is a novel intravaginal ring (IVR)

HC Wainwright & Co. Maintains Buy on Dare Bioscience, Raises Price Target to $6

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Douglas Tsao maintains Dare Bioscience (NASDAQ:DARE) with a Buy and raises the price target from $5 to $6.

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Contracts, Movers, Trading Ideas, General

Organon & Co (NYSE: OGN)

Recap: Dare Bioscience Q4 Earnings

Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Organon Enters Into Global License Agreement To Commercialize Daré Bioscience's XACIATO, FDA-Approved Treatment For Females 12 And Older With Bacterial Vaginosis

Biotech, News, Contracts, General

Organon (NYSE:OGN), a global women's healthcare company, and Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced they have entered into an agreement whereby Organon

Earnings Scheduled For March 31, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

Earnings Preview: Dare Bioscience

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.15.

Press releases

From Benzinga Pro

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

Earnings, Press Releases

$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for XACIATO™ (clindamycin phosphate

Organon Enters into Global License Agreement to Commercialize Daré Bioscience's XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

An estimated 21 million American women experience BV Organon (NYSE:OGN), a global women's healthcare company, and Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced they have